NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Splenic Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Recurrent Marginal Zone Lymphoma
Waldenström Macroglobulinemia
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma

Interventions: Biological: rituximab
Biological: yttrium Y 90 ibritumomab tiuxetan
Biological: indium In 111 ibritumomab tiuxetan
Biological: oprelvekin
Biological: filgrastim

First Posted Date: 2003-01-27

Last Posted Date: 2018-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 81

Registration Number: NCT00012298

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Untreated Adult Acute Myeloid Leukemia
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Secondary Acute Myeloid Leukemia

Interventions: Biological: oblimersen sodium
Drug: cytarabine
Drug: daunorubicin hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2015-12-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 32

Registration Number: NCT00039117

Locations: 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States

Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme

Phase 1

Completed

Conditions: Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma

Interventions: Drug: gefitinib
Radiation: radiation therapy
Other: laboratory biomarker analysis

First Posted Date: 2003-01-27

Last Posted Date: 2020-10-30

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 158

Registration Number: NCT00052208

Locations: 🇺🇸
Radiation Therapy Oncology Group, Philadelphia, Pennsylvania, United States

R(+)XK469 in Treating Patients With Advanced Neuroblastoma

Phase 1

Completed

Conditions: Disseminated Neuroblastoma
Localized Unresectable Neuroblastoma
Recurrent Neuroblastoma
Regional Neuroblastoma

Interventions: Drug: R(+)XK469

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 85

Registration Number: NCT00028522

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

Geldanamycin Analogue in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Phase 1

Terminated

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Non-Hodgkin Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Adult Diffuse Small Cleaved Cell Lymphoma
Recurrent Adult Immunoblastic Large Cell Lymphoma
Recurrent Adult Lymphoblastic Lymphoma
Recurrent Grade 1 Follicular Lymphoma

Interventions: Drug: tanespimycin

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT00019708

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

Combination Chemotherapy in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: alvocidib
Drug: leucovorin calcium
Drug: fluorouracil
Drug: irinotecan hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT00021073

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: oxaliplatin
Drug: leucovorin calcium
Drug: fluorouracil
Drug: capecitabine
Other: pharmacological study

First Posted Date: 2003-01-27

Last Posted Date: 2013-12-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 50

Registration Number: NCT00043121

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura

Phase 1

Completed

Conditions: Esophageal Cancer
Lung Cancer
Malignant Mesothelioma
Metastatic Cancer

First Posted Date: 2003-01-27

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019825

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇺🇸
Center for Cancer Research, Bethesda, Maryland, United States

Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Duct Cell Adenocarcinoma of the Pancreas
Stage IV Pancreatic Cancer

Interventions: Drug: bortezomib
Drug: gemcitabine hydrochloride

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 88

Registration Number: NCT00052689

Locations: 🇺🇸
North Central Cancer Treatment Group, Rochester, Minnesota, United States

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

Phase 1

Completed

Conditions: Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Lymphoblastic Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions: Drug: cytarabine
Drug: mitoxantrone hydrochloride
Drug: alvocidib
Other: pharmacological study
Other: laboratory procedure

First Posted Date: 2003-01-27

Last Posted Date: 2013-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT00016016

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

Home Terms & Conditions Privacy Policy